Discovering new NASH medicines using 3D culture technology

Strategic and technical consulting for the biotech industry

Discovering medicines using high fidelity, 3D models of IBD

Science-driven drug discovery across multiple protein / tissue targets• Clinical trial design, biomarker and genetics implementation throughout clinical development • Led early screening, characterization and profiling for multiple preclinical compounds• Translational science lead for novel biologic therapeutic• Multiple compounds advanced from discovery into clinical trials

• Responsible for pharmacology and biomarker aspects of MEK discovery, translational and clinical development, resulting in a successful sale to Bayer after Phase 2.• Built successful preclinical inflammation/immunology portfolio in arthritis, IBD (UC and Crohns) and asthma. • Utilized internal and external preclinical cancer models to define efficacy, synergy, dose selection and biomarker profiling for prostate, pancreatic and hepatocellular carcinoma.• Successful biomarker and development through preclinical validation, incorporation and implementation in clinical trials including CTC's, plasma based biomarkers, hair follicle based assays and ex vivo PBMC assays / tumor biopsy genotyping

Worked in a series of roles of increasing responsibility targeting receptor-based drug discovery